Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors

Human Pathology

Volumn 40, Issue 6, 2009, Pages 783-794

  López Terrada, Dolores ^a   Gunaratne, Preethi H ^a,b   Adesina, Adekunle M ^a   Pulliam, Joseph ^a   Hoang, David M ^b   Nguyen, Yummy ^a   Mistretta, Toni Ann ^a   Margolin, Judith ^a   Finegold, Milton J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Houston   (United States)

Author keywords

DLK1; Hepatoblastoma; Liver development; Notch; Wnt

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 4ALPHA; NOTCH RECEPTOR; WNT PROTEIN;

ARTICLE; CANCER CLASSIFICATION; CCND1 GENE; CHILD; CTNNB1 GENE; DIFFERENTIAL DISPLAY; DKK GENE; DLK1 GENE; EGFR GENE; FEMALE; GENE; GENE DELETION; GENE OVEREXPRESSION; GLUL GENE; HEPATOBLASTOMA; HES1 GENE; HUMAN; HUMAN TISSUE; IGF2 GENE; INFANT; LIVER CELL; MALE; MALIGNANT TRANSFORMATION; NEWBORN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; PROTEIN EXPRESSION; UPREGULATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BETA CATENIN; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATOBLASTOMA; HEPATOCYTE NUCLEAR FACTOR 4; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR II; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; WNT PROTEINS;

EID: 67349272856     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.07.022     Document Type: Article

References (35)

1. Mann J.R., Kasthuri N., Raafat F., et al. Malignant hepatic tumours in children: incidence, clinical features and aetiology. Paediatr Perinat Epidemol 4 (1990) 276-289
2. Weinberg A.G., and Finegold M.J. Primary hepatic tumors of childhood. Hum Pathol 14 (1983) 512-537
3. Lopez-Terrada D., and Finegold M.J. Tumors of the liver. In: Balisteri, et al. (Ed). Liver disease in children (2006), Cambridge University Press, New York, USA 943-976
4. Haas J.E., Feusner J.H., and Finegold M.J. Small cell undifferentiated histology in hepatoblastoma may be unfavourable. Cancer 92 (2001) 3130-3134
5. Buckley J.D., Sather H., Ruccione K., et al. A case control study of risk factors for hepatoblastoma. A report from the Childrens Cancer Study Group. Cancer 64 (1989) 1169-1176
6. Schneider N.R., Cooley L.D., Finegold M.J., Douglass E.C., and Tomlinson G.E. The first recurring chromosome translocation in hepatoblastoma: der(4)t(1;4)(q12;q34). Genes Chromosomes Cancer 19 (1997) 291-294
7. Terracciano L.M., Bernasconi B., Ruck P., et al. Comparative genomic hybridization analysis of hepatoblastoma reveals high frequency of X-chromosome gains and similarities between epithelial and stromal components. Hum Pathol 34 (2003) 864-871
8. Luo J.H., Ren B., Keryanov S., et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44 (2006) 1012-1024
9. Maris J.M., and Denny C.T. Focus on embryonal malignancies. Cancer Cell 2 (2002) 447-450
10. Reguart N., He B., Taron M., You L., Jablons D.M., and Rosell R. The role of Wnt signaling in cancer and stem cells. Future Oncol 1 (2005) 787-797
11. Thompson M.D., and Monga S.P. WNT/beta catenin signaling in liver health and disease. Hepatology 45 (2007) 1298-1305
12. Calvisi D.F., Conner E.A., Ladu S., Lemmer E.R., Factor V.M., and Thorgeirsson S.S. Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc./E2F1 transgenic mouse model of liver cancer. J Hepatol 42 (2005) 842-849
13. Tan X., Yuan Y., Zeng G., et al. Beta-catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival during mouse development. Hepatology 47 (2008) 1667-1679
14. Devereux T.R., Anna C.H., Foley J.F., White C.M., Sills R.C., and Barrett J.C. Mutation of beta catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Onogene 18 (1999) 4726-4733
15. Calvisi D.F., Factor V.M., Loi R., and Thorgeirsson S.S. Activation of beta catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res 61 (2001) 2085-2091
16. Koch A., Denkhaus D., Albrecht S., Leuschner I., von Schweinitz D., and Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 59 (1999) 269-273
17. Park W.S., Oh R.R., Park J.Y., et al. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol 193 (2001) 483-490
18. Galceran J., Sustmann C., Hsu S.C., Folberth S., and Grosschedl R. LEF-1 mediated regulation of Delta-like 1 links Wnt and Notch signaling in somitogenesis. Genes Dev 18 (2004) 2718-2723
19. Battle M.A., Konopka G., Parviz F., et al. Hepatocyte nuclear factor 4 alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A 103 (2006) 8419-8424
20. Anna C.H., Iida M., Sills R.C., and Devereux T.R. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice. Toxicol Appl Pharmacol 190 (2000) 135-145
21. Dabuko G.D., Mazerolle C.J., and Wallace V.A. Expression of Notch and Wnt pathway components and activation of Notch signaling in medulloblastomas from heterozygous patched mice. J Neurooncol 79 (2006) 221-227
22. Ayyanan A., Civenni G., Ciarloni L., et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism, proc. Natl Acad Sci U S A 103 (2006) 3799-3804
23. Jensen C.H., Jauho E.I., Santoni-Rugiu E., et al. Transit-amplifying ductular (oval) cells and their hepatocytic progeny are characterized by a novel and distinctive expression of delta-like protein/preadipocyte factor 1/fetal antigen 1. Am J Pathol 164 (2004) 1347-1359
24. Zatkova A., Rouillard J.M., Hartmann W., et al. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 39 (2004) 126-137
25. Prawitt D., Enklaar T., Gartner-Rupprecht B., et al. Microdeletion and IGF2 loss of imprinting in a cascade causing Beckwith-Wiedemann syndrome with Wilms' tumor. Nat Genet 37 (2005) 785-786 [author reply 86-7]
26. Tomizawa M., and Saisho H. Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma. World J Gastroenterol 12 (2006) 6531-6535
27. Dezso K., Halász J., Bisgaard H.C., et al. Delta-like protein (DLK) is a novel immunohistochemical marker for human hepatoblastomas. Virchows Arch 452 (2008) 443-448
28. Chambers J.M., Cleveland W.S., Kleiner B., and Tukey P.A. Graphical methods for data analysis (1983), Wadsworth International Group, Beltmont, CA, USA
29. Provost E., McCabe A., Stern J., Lizardi I., D'Aquila T.G., and Rimm D.L. Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin. Oncogene 24 (2005) 2667-2676
30. Kramps T., Peter O., Brunner E., et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 109 (2002) 47-60
31. Cadoret A., Ovejero C., Terris B., et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21 (2002) 8293-8301
32. Koch A., Waha A., Hartmann W., et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 11 (2005) 4295-4304
33. Akiyama H., Lyons J.P., Mori-Akiyama Y., et al. Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev 18 (2004) 1072-1087
34. Boyer J., Crosnier C., Driancourt C., et al. Expression of mutant JAGGED1 alleles in patients with Alagille syndrome. Hum Genet 116 (2005) 445-453
35. Tanimizu N., and Miyajima A. Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J Cell Sci 117 (2004) 3165-3174